135 related articles for article (PubMed ID: 6104914)
21. Ergot alkaloids inhibit 3H-naloxone binding to opiate receptors in the rat striatum and hippocampus.
Kosar E; Sumová A; Jakoubek B
Physiol Bohemoslov; 1986; 35(4):334-9. PubMed ID: 3020603
[TBL] [Abstract][Full Text] [Related]
22. Dopamine receptor stimulating effects of chanoclavine analogues, tricyclic ergot alkaloids, in the brain.
Watanabe H; Somei M; Sekihara S; Nakagawa K; Yamada F
Jpn J Pharmacol; 1987 Dec; 45(4):501-6. PubMed ID: 3127619
[TBL] [Abstract][Full Text] [Related]
23. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
[TBL] [Abstract][Full Text] [Related]
24. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors.
Fuxe K; Fredholm BB; Agnati LF; Corrodi H
Brain Res; 1978 May; 146(2):295-311. PubMed ID: 647392
[TBL] [Abstract][Full Text] [Related]
25. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.
Broderick PA; Olabisi OA; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):547-57. PubMed ID: 15093963
[TBL] [Abstract][Full Text] [Related]
26. Monoaminergic involvement in the behavioral effects of ergot derivatives.
Appel JB; Cunningham KA; West KB
Prog Clin Biol Res; 1985; 192():51-62. PubMed ID: 2867556
[TBL] [Abstract][Full Text] [Related]
27. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
Goldstein M; Lew JY; Hata F; Lieberman A
Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
[TBL] [Abstract][Full Text] [Related]
28. Neuropharmacology of synthetic ergot derivatives in man.
Lemberger L; Crabtree RE
Adv Biochem Psychopharmacol; 1980; 23():117-24. PubMed ID: 6104905
[No Abstract] [Full Text] [Related]
29. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
Oda T; Kume T; Izumi Y; Takada-Takatori Y; Niidome T; Akaike A
Eur J Pharmacol; 2008 Nov; 598(1-3):27-31. PubMed ID: 18835264
[TBL] [Abstract][Full Text] [Related]
30. Alteration of high-affinity binding sites of neurotransmitter receptors in rats after neonatal exposure to streptomycin.
Seth PK; Alleva FR; Balazs T
Neurotoxicology; 1982 Nov; 3(3):13-9. PubMed ID: 6298678
[TBL] [Abstract][Full Text] [Related]
31. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
32. Effects of ergot drugs on serotonergic function: behavior and neurochemistry.
Silbergeld EK; Hruska RE
Eur J Pharmacol; 1979 Sep; 58(1):1-10. PubMed ID: 315322
[TBL] [Abstract][Full Text] [Related]
33. Multiple 3H-5-hydroxytryptamine binding sites in rat brain.
Nelson DL; Pedigo NW; Yamamura HI
J Physiol (Paris); 1981; 77(2-3):369-72. PubMed ID: 7288652
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the central effects of ergot alkaloids by means of electroencephalography.
Longo VG; Loizzo A
Pharmacology; 1978; 16 Suppl 1():189-92. PubMed ID: 643900
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine.
Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
Acta Endocrinol Suppl (Copenh); 1978; 216():27-56. PubMed ID: 347864
[No Abstract] [Full Text] [Related]
36. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.
Reches A; Burke RE; Kuhn CM; Hassan MN; Jackson VR; Fahn S
J Pharmacol Exp Ther; 1983 Jun; 225(3):515-21. PubMed ID: 6864517
[TBL] [Abstract][Full Text] [Related]
37. Effects of subchronic antidepressant drug treatment on central serotonergic mechanisms in the male rat.
Fuxe K; Ogren SO; Agnati LF; Andersson K; Eneroth P
Adv Biochem Psychopharmacol; 1982; 31():91-107. PubMed ID: 7080902
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
[TBL] [Abstract][Full Text] [Related]
39. Lasting changes in high affinity 3H-spiperone binding to the rat striatum and mesolimbic area after chronic methamphetamine administration: evaluation of dopaminergic and serotonergic receptor components.
Akiyama K; Sato M; Kashihara K; Otsuki S
Biol Psychiatry; 1982 Dec; 17(12):1389-402. PubMed ID: 7159638
[TBL] [Abstract][Full Text] [Related]
40. Anorectic effect of lisuride and other ergot derivatives in the rat.
Carruba MO; Ricciardi S; Müller EE; Mantegazza P
Eur J Pharmacol; 1980 Jun; 64(2-3):133-41. PubMed ID: 6105081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
